Active Recombinant Human MYC
Cat.No. : | MYC-1028H |
- Specification
- Gene Information
- Related Products
Cat. No. : | MYC-1028H |
Description : | The universal deregulation of c-myc gene expression in tumor cells suggests that this oncogene represents an attractive target for cancer therapeutic purposes. The structural and biochemical features of the MYC family (MYC, N-MYC, and L-MYC) mark them as direct regulators of gene expression. As basic helix-loop-helix leucine zipper proteins (bHLH-ZIP), the MYCs acquire the capacity to bind the DNA sequence CACGTG (E-box) when dimerized with MAX (another bHLH-ZIP). A head-to- tail pair of MYC-MAX dimers may, in turn, form a heterotetramer capable of bridging distant E-boxes. Among the broadly distributed positive enforcers of MYC action that are often recruited to target genes are chromatin remodeling (SWI/SNF relatives) and modifying complexes (TRAPP/GCN5 and relatives); these complexes mobilize nucleosomes and acetylate histones and/or other targets to activate gene expression. MYC binds TBP along an auxiliary pathway to control gene expression. MAD and MNT generally oppose MYC action by enlisting histone deacetylase complexes. Besides acting at the level of chromatin, MYC may also operate at later stages of the transcription cycle, after pre-initiation complex formation. In addition to using generic chromatin complexes to up- or down-regulate transcription, the MYC network also conscripts individual factors to modify expression locally on an ad hoc basis. For example, YY1, AP2, MIZ1, SP1, BRCA1, and other proteins interact directly with MYC, and so may directly modify the output of the MYC network. Recombinant c-myc was expressed in a baculovirus system and purified by an affinity column in combination with FPLC chromatography. The purified recombinant protein is greater than 90% homogeneous and contains no detectable protease, DNase, and RNase activity. |
Source : | Sf9 insect cells. |
Application : | C-myc has been applied in DNA and protein-protein interaction assays. |
Usage : | For in vitro use only. |
Form : | Liquid. Supplied in 20 mM Tris-HCl pH 8.0, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT, 20% glycerol. |
Activity : | 100 ng are sufficient for a protein-protein interaction assay. |
Purity : | > 95% by SDS-PAGE. |
Storage : | Quality guaranteed for 12 months, Store at -80°C. Avoid freeze / thaw cycles. |
Gene Name : | MYC v-myc myelocytomatosis viral oncogene homolog (avian) [ Homo sapiens ] |
Synonyms : | MYC; v-myc myelocytomatosis viral oncogene homolog (avian); MRTL; c-Myc; bHLHe39; avian myelocytomatosis viral oncogene homolog; v-myc avian myelocytomatosis viral oncogene homolog; myc-related translation/localization regulatory factor |
Gene ID : | 4609 |
mRNA Refseq : | NM_002467 |
Protein Refseq : | NP_002458 |
MIM : | 190080 |
UniProt ID : | P01106 |
Chromosome Location : | 8q24 |
Pathway : | Acute myeloid leukemia; Bladder cancer; Chronic myeloid leukemia; Colorectal cancer; ErbB signaling pathway; Colorectal cancer; Jak-STAT signaling pathway; MAPK signaling pathway; Pathways in cancer; Small cell lung cancer; Small cell lung cancer; Thyroid cancer; Wnt signaling pathway |
Function : | protein binding; transcription factor activity |
Products Types
◆ Recombinant Protein | ||
MYC-1461H | Recombinant Human MYC Protein, His (Fc)-Avi-tagged | +Inquiry |
MYC-060H | Recombinant Human MYC Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
MYC-32H | Recombinant Active Human c-Myc Protein (1-454) | +Inquiry |
MYC-3498R | Recombinant Rat MYC Protein, His (Fc)-Avi-tagged | +Inquiry |
MYC-5787H | Recombinant Human MYC Protein, GST-tagged | +Inquiry |
◆ Lysates | ||
MYC-4039HCL | Recombinant Human MYC 293 Cell Lysate | +Inquiry |
◆ Assay kits | ||
Kit-1785 | Myc Reporter Kit (Myc Signaling Pathway) | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionAbnormal expression of MYC gene may affect the occurrence and progression of cardiovascular diseases such as atherosclerosis by regulating the proliferation of vascular smooth muscle cells and increasing the expression of endothelial cell-specific shear-related proteins.
Because of its important promotion role in pancreatic cancer, MYC gene is regarded as one of the potential targets and drug treatment directions for pancreatic cancer treatment, but specific research and related drugs need to be further verified.
The MYC gene may affect the proliferation of somatic cells by regulating cell cycle progression, such as increasing the S-phase entry of the cell cycle and promoting the G1/S phase transition.
Overexpression and defect of MYC in gastric cancer are associated with the occurrence, progression and prognosis of gastric cancer. MYC translocation and high expression predict a poor prognosis.
MYC gene may be involved in the proliferation and differentiation of hematopoietic stem cells, but the specific mechanism and role still need to be further elucidated.
Abnormal expression of MYC gene may affect tumor progression and prognosis by activating cell cycle constants, apoptosis inhibition, and enhanced cell mobility.
Customer Reviews (3)
Write a reviewThe reproducibility of MYC is very good, and the results remain consistent even after repeated experiments several times, which gives me more confidence in the experimental results.
Stability of this protein was still very good when different chemicals or drugs were added, indicating its excellent anti-interference ability and stability.
Due to stability of MYC in Western blot was very good and even prolonged storage did not affect its performance.
Ask a Question for All MYC Products
Required fields are marked with *
My Review for All MYC Products
Required fields are marked with *
Inquiry Basket